文献速递骨质疏松与钙磷/甲状旁腺

钙敏感受体基因杂合突变(Q459R)导致家族性低尿钙性高钙血症1型(FHH1)

Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1).
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

研究识别一个携带CASR Q459R杂合突变的家族,3名杂合携带者均有轻度无症状高钙血症和低尿钙,2例血清甲状旁腺素(PTH)升高;体外HEK293A细胞实验显示Q459R为功能丧失性突变,不影响细胞表面表达,纯合子IP1信号钙敏感性显著降低,杂合子也降低但未达统计学显著。结论认为该突变导致FHH1,钙模拟剂可能对该突变患者有效。

要点

  • 3名CASR Q459R杂合携带者均表现为轻度无症状高钙血症和低尿钙,其中2例PTH升高。
  • 体外实验显示Q459R为功能丧失性突变,不影响CaSR细胞表面表达。
  • 纯合Q459R细胞IP1信号钙敏感性较野生型显著降低,杂合Q459R也降低但未达统计学显著。

核心结论

  • CASR Q459R功能丧失性突变在一个家族中导致FHH1,特征为离子钙和PTH升高及钙排泄降低。
  • 体外CaSR在膜上明显存在且IP1信号受抑制,提示钙模拟剂可能对该突变患者有功能。
  • 该突变似乎是与FHH1常染色体显性遗传相关的轻度功能丧失性突变。

研究设计与样本

  • 对先证者及其家族进行临床、生化和遗传学分析。
  • 在瞬时转染的人胚胎肾293A(HEK293A)细胞中,通过测定CaSR细胞表面表达和肌醇单磷酸(IP1)信号,对纯合和杂合Q459R突变进行体外功能鉴定。

主要发现

  • 所有3名杂合携带者均有轻度无症状高钙血症和低尿钙,其中2例血清PTH升高。
  • 体外HEK293A细胞鉴定显示CASR Q459R为功能丧失性突变,对细胞表面表达无影响。
  • 纯合Q459R基因型细胞的IP1信号钙敏感性较野生型显著降低,杂合Q459R的钙敏感性也较低但与野生型无显著差异。

临床怎么用

  • 作者认为,体外CaSR在膜上明显存在且IP1信号受抑制,提示钙模拟剂可能对该突变患者有功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Several heterozygous loss-of-function mutations in the calcium-sensing receptor gene (CASR) leading to elevated ionized serum calcium and familial hypocalciuric hypercalcemia 1 (FHH1) have been characterized. Few mutations are not pathogenic, and previous studies suggested that the Q459R mutation does not result in an FHH1 phenotype. OBJECTIVE: We identified a family with a heterozygous CASR Q459R mutation and characterized their calcium homeostasis and the pathophysiological mechanisms of a homozygous and heterozygous Q459R mutation in vitro. DESIGN: The index patient and her family had clinical, biochemical, and genetic analyses performed. In vitro functional characterization of homozygous and heterozygous (Q459R) mutations was conducted by determining CaSR cell-surface expression and inositol monophosphate (IP1) signaling in transiently transfected human embryonic kidney 293A (HEK293A) cells. RESULTS: All 3 heterozygous carriers had mild asymptomatic hypercalcemia, hypocalciuria, and 2 had elevated serum parathyroid hormone (PTH). In vitro characterization in HEK293A cells revealed that CASR Q459R is a loss-of-function mutation with no impact on cell-surface expression. Cells with the homozygous Q459R genotype had significantly reduced calcium potency of IP1 signaling compared to wild type, whereas the heterozygous Q459R also had lower calcium potency albeit not significantly different from wild type. CONCLUSION: A loss-of-function Q459R mutation in CASR in a family caused FHH1 characterized by elevated ionized calcium and PTH and low calcium excretion. The marked presence of CaSR at the membrane and inhibition of IP1 signaling in vitro suggest that calcimimetics may be functional in patients with this mutation, which seems to be a mild loss-of-function mutation associated with autosomal dominant transmission of FHH1.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Boisen IM, Mos I, Lerche-Black EM, et al. Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1). J Clin Endocrinol Metab. 2020. PMID: 32160303. doi:10.1210/clinem/dgz205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。